Ferring Pharmaceuticals, Inc.

A phase 3b clinical trial demonstrated that Rebyota (fecal microbiota, live-jslm) administered via colonoscopy achieved a 95.1% treatment success rate in preventing recurrent C. difficile infection.

The IRIS study represents the world's first randomized controlled trial specifically evaluating ovarian stimulation protocols in Indian infertile patients, addressing a historically under-researched population.

The FDA has approved Ferring Pharmaceuticals' new drug product manufacturing hub in Parsippany, NJ, for production of ADSTILADRIN, the first FDA-approved intravesical gene therapy for high-risk BCG-unresponsive bladder cancer.

Nadofaragene firadenovec demonstrated a 75% complete response rate at 3 months in Japanese patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, according to new Phase 3 trial data.

• The endometriosis clinical trial landscape is robust, featuring over 15 companies developing more than 20 potential therapies. • Recent clinical trial activity includes positive Phase II results for Hope Medicine's HMI-115 and TiumBio's Merigolix, alongside Lisata Therapeutics' preclinical research. • Key companies like Kissei Pharmaceutical, Mithra Pharmaceuticals, and Organon are advancing novel treatments, including Linzagolix and Estelle, to address unmet needs. • These emerging therapies aim to improve pain management and overall outcomes for the estimated 190 million women affected by endometriosis worldwide.

• Real-world data presented at ID Week 2024 confirms the continued efficacy and safety of Rebyota, a live biotherapeutic product, for recurrent Clostridioides difficile infection (rCDI) two years post-approval. • Research indicates reduced vancomycin susceptibility in Clostridioides difficile isolates correlates with diminished sustained clinical response, emphasizing the need for alternative treatment strategies. • Vedanta Biosciences has commenced a Phase 3 clinical trial (RESTORATiVE303) evaluating VE303, a live biotherapeutic product, for preventing recurrent Clostridioides difficile infection (rCDI). • A study showed that oral vancomycin prophylaxis significantly reduces Clostridioides difficile infection incidence during hospitalization for autologous stem cell transplant recipients.

Real-world data presented at the 2025 ASCO Genitourinary Cancers Symposium indicates nadofaragene firadenovec demonstrates positive efficacy and safety outcomes in treating NMIBC.

Ferring Pharmaceuticals is expanding the clinical trial program for nadofaragene firadenovec, an intravesical gene therapy, to include intermediate-risk NMIBC and low-grade UTUC.

• Clinical trials are actively progressing for Fabry Disease, with companies like Idorsia and Sanofi Genzyme developing novel therapies. • Emerging treatments like Venglustat and Pegunigalsidase alfa are expected to significantly impact the Fabry Disease market in the coming years. • Research and development efforts are also focused on Clostridium Difficile Infections, with Vedanta Biosciences leading Phase 3 trials for VE303. • Mydriasis treatments are advancing, with companies like Eyenovia exploring solutions like MYDCOMBI for pupil dilation.

REBYOTA, a live biotherapeutic product, continues to demonstrate efficacy in preventing recurrent Clostridioides difficile infection (rCDI) two years post-FDA approval.